

1 **Impact of SARS-CoV-2 infection on longitudinal vaccine immune responses**

2

3 Sebastian Havervall, MD<sup>1</sup>, Ulrika Marking, MD<sup>1</sup>, Nina Greilert-Norin, RN<sup>1</sup>, Max  
4 Gordon, MD, PhD<sup>1</sup>, Henry Ng, MMSc<sup>1,2</sup>, Wanda Christ, MMSc<sup>3</sup>, Kim Blom, PhD<sup>1,4</sup>,  
5 Mia Phillipson, PhD<sup>2</sup>, Peter Nilsson, PhD<sup>5</sup>, Sophia Hober, PhD<sup>5</sup>, Jonas Klingström,  
6 PhD<sup>3,4</sup>, Sara Mangsbo, PhD<sup>6</sup>, Mikael Åberg<sup>#</sup>, PhD<sup>7</sup>, and Charlotte Thålin<sup>#</sup>, MD, PhD<sup>1</sup>

7

8

9 1. Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital,

10 Stockholm, Sweden

11 2. Department of Medical Cell Biology and SciLifeLab, Uppsala University, Uppsala,

12 Sweden

13 3. Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska

14 Institutet, Stockholm, Sweden

15 4. Department of Microbiology, Public Health Agency of Sweden, Solna, Sweden

16 5. Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab,

17 Stockholm, Sweden

18 6. Department of Pharmacy and SciLifeLab, Uppsala University, Uppsala, Sweden

19 7. Department of Medical Sciences, Clinical Chemistry and SciLifeLab, Uppsala

20 University, Uppsala, Sweden

21

22 <sup>#</sup> These authors contributed equally

23

24

25 **Corresponding author:**

26 Charlotte Thålin, MD, PhD

27 Department of Clinical Sciences

28 Karolinska Insitutet

29 18288 Danderyd Hospital

30 Sweden

31 Phone: +46 8123 55000

32 Mail: charlotte.thalin@ki.se

33

34

35 **Abstract**

36 **Background**

37 Recent serological investigations imply waning immune responses following SARS-  
38 CoV-2 vaccination, but prior infection may impact the breadth and duration of vaccine  
39 immune responses.

40

41 **Methods**

42 Using longitudinally collected blood samples from the COMMUNITY study, we  
43 determined binding (WHO BAU/ml) and neutralizing antibody titers against ten  
44 SARS-CoV-2 variants over seven months following BNT162b2 in healthcare workers  
45 with (n=111) and without (n=298) confirmed prior SARS-CoV-2 infection. A smaller  
46 group with (n=47) and without (n=61) confirmed prior SARS-CoV-2 infection  
47 receiving ChAdOx1 nCoV-19 was followed for three months.

48

49 **Results**

50 Vaccination (BNT162b2 and ChAdOx1 nCoV-19) following SARS-CoV-2 infection  
51 resulted in higher wild-type BAU/ml geometric mean titers (GMTs) at all sampling  
52 time points when compared to SARS-CoV-2 naïve vaccinees (all  $p < 0.001$ ). GMTs  
53 were 1875 BAU/ml in convalescent and 981 BAU/ml in naïve BNT162b2 vaccinees 6  
54 weeks post vaccination. 29 weeks post vaccination, GMTs had decreased to 524  
55 BAU/ml in convalescent and 148 BAU/ml in naïve vaccinees. GMT differences  
56 between convalescents and naïve following ChAdOx1 nCoV-19 mirrored those after  
57 BNT162b2, but the titers were 4.5-fold lower following ChAdOx1 nCoV-19 as  
58 compared to those after BNT162b2 ( $p < 0.001$ ). Finally, at all time points, neutralizing  
59 antibody titers against all ten tested SARS-CoV-2 variants were at least 2  
60 respectively 3-fold higher in SARS-CoV-2 recovered as compared to naïve vaccinees  
61 following BNT162b2 and ChAdOx1 nCoV-19, respectively (all  $p < 0.001$ ).

62

63 **Conclusions**

64 These findings of substantially more robust serological responses to vaccine after  
65 natural infection imply that prior infection may be taken into consideration when  
66 planning booster doses and design of current and future SARS-CoV-2 vaccine  
67 programs.

## 68 **Introduction**

69 Clinical trials and post marketing effectiveness data have shown that currently used  
70 COVID-19 vaccines protect strongly against hospitalization and death in most  
71 settings<sup>1-3</sup>. However, real-world efficacy estimates are affected by population  
72 demographics, characteristics of circulating SARS-CoV-2 variants, vaccine protocols  
73 and time since vaccination. An increased risk of breakthrough infections is now  
74 observed, partly explained by immune waning<sup>4-8</sup>. A robust immune response after  
75 infection or vaccination is based on the induction of memory B and T cells generating  
76 virus specific antibodies and T-cell responses<sup>9-13</sup>. Antibody levels have been shown  
77 to correlate inversely with risk of SARS-CoV-2 infection<sup>14,15</sup> and may, with  
78 standardized readouts<sup>16</sup>, be used as a marker for correlates of protection. Time  
79 between prime and boost<sup>17</sup>, the number of boosters administered as well as  
80 infection prior to vaccination<sup>18</sup> impact the breadth and duration of immune  
81 responses. As an increasing number of persons become infected globally,  
82 vaccination post SARS-CoV-2 infection will become more frequent. Prior SARS-CoV-  
83 2 infection has been reported to positively impact vaccine responses<sup>9,19-24</sup> but little is  
84 known regarding long term effects. Although available vaccines have been proven  
85 safe and efficacious, they are not free of unforeseen adverse events<sup>25,26</sup>. To  
86 optimize immunization programs, it is therefore crucial to study duration of immune  
87 responses including direct comparisons of vaccine platforms and the long-term effect  
88 of prior SARS-CoV-2 infection on subsequent vaccine-induced responses in real  
89 world evidence studies.

90

91 Using longitudinally collected blood samples from the COMMUNITY (COVID-19  
92 Immunity) study<sup>13,24,27,28</sup> we herein report binding and pseudo-neutralizing antibody  
93 titers elicited over seven months following mRNA BNT162b2 (Comirnaty, Pfizer  
94 BioNTech) and over three months following adenovirus-vectored ChAdOx1 nCoV-19  
95 (Vaxzevria, AstraZeneca) vaccination in 517 healthcare workers (HCW) with and  
96 without confirmed SARS-CoV-2 infection prior to vaccination.

97

## 98 **Methods**

### 99 ***Study population***

100 The COMMUNITY study enrolled 2149 HCW at Danderyd Hospital, Stockholm,  
101 Sweden, in April and May 2020. SARS-CoV-2 spike-specific IgG are analyzed every

102 four months by multiplex antigen bead array<sup>29</sup>. All HCW at Danderyd Hospital were  
103 offered vaccination with either BNT162b2 or ChAdOx1 nCoV-19, depending on  
104 availability, starting January 2021. Date and type of vaccine was obtained through  
105 the Swedish vaccination register (VAL Vaccinera).

106

107 This sub-study included a total of 517 HCW stratified into two groups depending on  
108 SARS-CoV-2 infection prior to vaccination. Previous SARS-CoV-2 infection was  
109 confirmed by SARS-CoV-2 spike-specific IgG seroconversion at any of the four-  
110 month follow-ups since study inclusion in April 2020. 337 HCW received BNT162b2  
111 with a 3-week dose interval (range 21-28 days) between January 12<sup>th</sup> and February  
112 24<sup>th</sup>, 2021. These were sampled at 6 weeks (range 5-8 weeks; 69 SARS-CoV-2  
113 naïve and 27 SARS-CoV-2 recovered vaccinees), 12 weeks (range 11-14 weeks;  
114 175 SARS-CoV-2 naïve and 52 SARS-CoV-2 recovered) and 29 weeks (range 27-30  
115 weeks; 246 SARS-CoV-2 naïve vaccinees and 68 SARS-CoV-2 recovered) post  
116 second BNT162b2 dose, respectively. 72 HCW received BNT162b2 with a 6-week  
117 dose interval (range 39-52 days) between April 17<sup>th</sup> and July 2<sup>nd</sup>, 2021 and were  
118 sampled at 12 weeks (range 11-14 weeks; 36 SARS-CoV-2 naïve and 36 SARS-  
119 CoV-2 recovered) post second BNT162b2 dose. ChAdOx1 nCoV-19 vaccinees were  
120 fully vaccinated at a later time point than BNT162b2 vaccinees, between February  
121 25<sup>th</sup> and May 31<sup>st</sup>, 2021. 108 HCW received ChAdOx1 nCoV-19 with a 12-week dose  
122 interval (range 71-92 days) and were sampled at 3 weeks (range 2-3 weeks; 48  
123 SARS-CoV-2 naïve and 35 SARS-CoV-2 recovered) and 14 weeks (range 13-15  
124 weeks; 56 SARS-CoV-2 naïve and 44 SARS-CoV-2 recovered) post second dose,  
125 respectively. Figure 1.

126

127 Demographics and vaccine status of the study population are presented in Table 1.  
128 The study is approved by the Swedish Ethical Review Authority (dnr 2020-01653)  
129 and written informed consent was obtained from all study participants.

130

131

### 132 ***Binding and pseudo-neutralizing antibodies***

133 Binding antibodies (IgG) and pseudo-neutralizing antibodies against SARS-CoV-2  
134 wild type (WT) and B.1.1.7 (Alpha), B.1.351 (Beta), B.1.526.1 (New York), B.1.617  
135 (India), B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.617.3 (India), P.1 (Gamma), and

136 P.2 (Zeta) variants, were measured in post vaccination samples using the V-PLEX  
137 SARS-CoV-2 Panel 13 (Meso Scale Diagnostics, USA) for IgG and ACE2  
138 (quantifying the ability to inhibit the binding between the ACE2 receptor and the spike  
139 protein), respectively. Binding antibody titers for WT were calibrated against the  
140 WHO standard<sup>16</sup> according to the manufacturer's instructions and presented as  
141 Binding Antibody Units (BAU)/ml. Pseudo-neutralizing antibodies are expressed as  
142 arbitrary units (AU)/ml.

143

#### 144 ***Microneutralization assay***

145 Microneutralization based on cytopathic effects (CPE) was performed essentially as  
146 previously described<sup>30</sup>. Briefly, serum was 3-fold serially diluted, mixed with virus,  
147 incubated for 1 hour and finally added, in duplicates, to confluent Vero E6 cells in 96-  
148 well plates. Original SARS-CoV-2 WT (isolated from a Swedish patient) and the Delta  
149 variant (from Statens Serum Institut, Copenhagen, Denmark), were used. After 5  
150 days incubation, the wells were inspected for signs of CPE by optical microscopy.  
151 Each well was scored as either neutralizing (if no signs of CPE was observed) or  
152 non-neutralizing (if any CPE was observed). The arithmetic mean neutralization titer  
153 of the reciprocals of the highest neutralizing dilutions from the two duplicates for each  
154 sample was then calculated.

155

#### 156 ***Statistical analyses***

157 Spike IgG and pseudo-neutralizing antibody titers are presented as geometric mean  
158 titers (GMTs) with 95% confidence interval (CI). Linear regression was used to  
159 compare continuous variables between groups and were adjusted for sex and age.  
160 Multiple samples per subject were analyzed using linear mixed effects regression  
161 with random intercepts per subject using the same adjustments as for linear  
162 regression. The correlation coefficient was calculated using Spearman's correlation  
163 analysis. Linear regression and mixed effects regressions were performed in R  
164 (version 4.1.1) with nlme-package version 3.1.152 and contrast-package 0.22 while  
165 the remainder were done in GraphPad Prism (version 9.1.1).

166

#### 167 **Results**

168 ***Antibody responses over seven months following BNT162b2 vaccination in***  
169 ***SARS-CoV-2 recovered and naïve individuals***

170 Almost all (99.8%) participants had detectable levels of spike IgG antibodies after  
171 vaccination. Notably, at all sampling time points, spike IgG GMTs were markedly  
172 higher in previously SARS-CoV-2 infected vaccinees compared to SARS-CoV-2  
173 naïve vaccinees (all  $p < 0.001$ ). Table 2 and Figure 2A. A decrease of spike IgG GMTs  
174 by 2-fold between week 6 and 12, and by 6.6-fold between week 6 and 29 were  
175 observed in SARS-CoV-2 naïve BNT162b2 vaccinees. This decrease was not as  
176 explicit in vaccinees with SARS-CoV-2 infection prior to vaccination, as GMTs  
177 decreased by 1.5-fold between week 6 and 12, and by 3.6-fold between week 6 and  
178 29 post vaccination.

179

180 Binding spike IgG titers correlated strongly to pseudo-neutralizing antibody titers  
181 against both the WT and the Delta variant (Spearman's rank correlation coefficient  
182 0.92, and 0.83, respectively, both  $p < 0.0001$ ). Consistent with spike IgG, substantially  
183 higher GMTs of pseudo-neutralizing antibodies were observed in vaccinees with  
184 SARS-CoV-2 infection prior to vaccination compared to SARS-CoV-2 naïve  
185 vaccinees at all sampling time points (all  $p < 0.001$ ). Table 2 and Figure 2B-C. Among  
186 SARS-CoV-2 naïve vaccinees, GMTs of pseudo-neutralizing antibodies against the  
187 WT and Delta variant decreased by 1.8-fold and 2.6-fold between week 6 and 12,  
188 and by 3.3-fold and 4.6-fold between week 6 and 29, respectively. For vaccinees with  
189 SARS-CoV-2 infection prior to vaccination, GMTs of pseudo-neutralizing antibodies  
190 against the WT and Delta variant decreased by 2.3-fold and 2.1-fold between weeks  
191 6 and 12, and by 5.1-fold and 3.6-fold between weeks 6 and 29, respectively. Table 2  
192 and Figure 2B-C. Notably, pseudo-neutralizing GMTs against the Delta variant  
193 reached similar levels and trajectories as pseudo-neutralizing GMTs against the WT,  
194 indicating a similar trend in response for the currently circulating Delta variant as for  
195 the initially circulating WT. Table 2 and Figure 2B-C.

196

### 197 ***Effect of BNT162b2 dose interval on antibody levels***

198 It has been reported that a longer interval between BNT162b2 doses can result in  
199 higher antibody titres<sup>31</sup>. In this cohort, BNT162b2 vaccinees were administered with  
200 a 3-4 week dose interval in January to February 2021, and with a prolonged dose  
201 interval of 6-8 weeks in April to July 2021.

202

203 12 weeks post second dose, there were no significant differences in spike IgG GMTs  
204 following BNT162b2 with the 3-4 week and the 6–8-week dose interval, regardless of  
205 prior SARS-CoV-2 infection (all  $p>0.05$ ). Table 2. Pseudo-neutralizing antibody  
206 GMTs against both the WT and Delta variant were, however, slightly but significantly  
207 increased 12 weeks following second dose after the prolonged dose interval  
208 ( $p=0.016$  and  $p=0.017$ , respectively) in SARS-CoV-2 naïve vaccinees when adjusted  
209 for sex and age. A similar trend was seen in SARS-CoV-2 recovered vaccinees,  
210 although the differences were not significant (all  $p>0.05$ ). Table 2.

211

212 ***Antibody responses over three months following ChAdOx1 nCoV-19***  
213 ***vaccination in SARS-CoV-2 recovered and naïve individuals***

214 As data following BNT162b2 vaccination displayed an improved long-term immune  
215 response in SARS-CoV-2 recovered individuals we also explored this in the context  
216 of the ChAdOx1 nCoV-19 vaccine. Spike IgG GMTs in SARS-CoV-2 naïve vaccinees  
217 were 4.5-fold lower following ChAdOx1 nCoV-19 as compared to those after  
218 BNT162b2 ( $p<0.001$ ). Similar to what was observed after BNT162b2 vaccination,  
219 spike IgG GMTs were substantially increased in SARS-CoV-2 recovered ChAdOx1  
220 nCoV-19 vaccinees compared to SARS-CoV-2 naïve vaccinees at all sampling time  
221 points (all  $p<0.001$ ). Table 2 and Figure 2A-C. In SARS-CoV-2 naïve vaccinees,  
222 spike IgG GMTs declined 1.9-fold between week 3 and 14 post vaccination, whereas  
223 GMTs declined 2.3-fold between week 3 and 14 post vaccination in SARS-CoV-2  
224 recovered vaccinees.

225

226 Consistent with binding antibodies, substantially higher GMTs of pseudo-neutralizing  
227 antibodies were observed in SARS-CoV-2 recovered ChAdOx1 nCoV-19 vaccinees  
228 compared to SARS-CoV-2 naïve vaccinees at all sampling time points (all  $p<0.001$ ).  
229 Table 2 and Figure 2 B-C. In SARS-CoV-2 naïve vaccinees, GMTs against the WT  
230 and Delta variant decreased by 1.4-fold and 3-fold between week 3 and 14,  
231 respectively, whereas they decreased by 1.3-fold and 1.5-fold, respectively, in SARS-  
232 CoV-2 recovered vaccinees. Similar to findings following BNT162b2 vaccination,  
233 GMTs against the Delta variant reached comparable levels and trajectories as GMTs  
234 against the WT. Table 2 and Figure 2 B-C.

235

236

237 ***Live-microneutralization compared to pseudo-neutralization***

238 As a slightly higher capacity to inhibit binding of the Delta variant compared to the  
239 WT was found using the pseudo-neutralizing assay (Figure 2B-C), a live-neutralizing  
240 assay was performed in a sub-set of 34 (17 SARS-CoV-2 naïve BNT162b2  
241 vaccinees and 17 SARS-CoV-2 naïve ChAdOx1 nCoV-19 vaccinees) participants.  
242 While results from these two assays correlated with regard to the WT and the Delta  
243 variant ( $rS=0.66$  and  $0.63$  respectively, both  $p<0.0001$ ), the live-microneutralization  
244 assay resulted in 25.2 % lower titres against the Delta variant compared to the WT.

245

246 ***Neutralization capacity against SARS-CoV-2 variants in vaccinees with and***  
247 ***without SARS-CoV-2 infection prior to vaccination***

248 In light of the substantial increases in antibody titres observed in SARS-CoV-2  
249 recovered vaccinees as compared to SARS-CoV-2 naïve vaccinees, we proceeded  
250 to determine if SARS-CoV-2 variants contributed differently. Pseudo-neutralizing  
251 antibody titres were assessed against ten SARS-CoV-2 variants, including all  
252 variants of concern (VOC) (B.1.1.7 (Alpha), B.135.1 (Beta), P.1 (Gamma) and  
253 B.1.617.2 (Delta)). Notably, neutralizing antibody titers against all ten tested SARS-  
254 CoV-2 variants were at least 2 respectively 3-fold higher in SARS-CoV-2 recovered  
255 as compared to naïve vaccinees following BNT162b2 and ChAdOx1 nCoV-19,  
256 respectively (all  $p<0.001$ ). Figure 3 A-C and Table S1.

257

258

259 **Discussion**

260 Using a large cohort with longitudinally collected blood samples following SARS-  
261 COV-2 vaccination, we show that vaccination following SARS-COV-2 infection  
262 resulted in remarkably and sustained higher antibody titres with an increased  
263 neutralizing potency and breadth against SARS-CoV-2 variants as compared to  
264 vaccination in SARS-COV-2 naïve individuals. Furthermore, we reveal a significant  
265 decline in BAU/ml and pseudo-neutralizing antibody titres over the first months  
266 following both ChAdOx1 nCoV-19 and BNT162b2 vaccination. Direct comparisons  
267 showed substantially lower titres following immunization with ChAdOx1 nCoV-19  
268 compared to BNT162b2. These findings are important for decisions on booster doses  
269 and design of current and future SARS-CoV-2 vaccine programs, as these should be

270 based on data from effectiveness studies and serological investigations calibrated  
271 against WHO standards.

272

273 We and others have previously shown that COVID-19 convalescents mount strong  
274 immune responses following mRNA<sup>9,19-23</sup> and adenovirus-vectored vaccines<sup>24</sup>. We  
275 here extend these findings by showing that antibody titres remain substantially  
276 increased over three months following ChAdOx1 nCoV-19, and seven months  
277 following BNT162b2 in SARS-CoV-2 infected HCW with mild disease prior to  
278 vaccination. This suggests that the immune-strengthening effect of exposure to  
279 infection followed by vaccination is not a temporary phenomenon. It was recently  
280 demonstrated that the memory compartment continues to evolve after both natural  
281 infection and vaccination, but with a lesser increase in breadth following vaccination  
282 as compared to infection<sup>18</sup>. Importantly, we found that SARS-CoV-2 recovered  
283 vaccinees developed antibodies capable of neutralizing SARS-CoV-2 variants to a  
284 higher extent than SARS-CoV-2 naïve vaccinees. Neutralizing capacity against ten  
285 SARS-CoV-2 variants analysed, including all four VOCs, remained substantially  
286 higher in SARS-CoV-2 recovered vaccinees as compared to SARS-CoV-2 naïve  
287 vaccinees throughout the study period. Although vaccinated SARS-CoV-2 recovered  
288 individuals may eventually need a booster, these findings suggest that vaccine in  
289 immune competent SARS-CoV-2 recovered evokes antibody levels that are sufficient  
290 for protection during a longer time period than those rendered in SARS-CoV-2 naïve  
291 vaccinees.

292

293 Our findings of substantial reductions in antibody titres over the first three months  
294 following ChAdOx1 nCoV-19 and seven months following BNT162b2 are in line with  
295 several reports of waning vaccine efficacy from countries including Israel<sup>4,5</sup>, UK<sup>6,7</sup>  
296 and the US<sup>8</sup>. The comparatively lower titres following ChAdOx1 nCoV-19 are also in  
297 line with prior data on lower vaccine efficacy of adenovirus vector-based vaccines as  
298 compared to mRNA vaccines<sup>2,32</sup>. Specific antibody levels are used as a correlate of  
299 protection against infection following several established vaccines<sup>33</sup>, and for SARS-  
300 CoV-2, binding and pseudo-neutralizing antibody titres correlate inversely with risk of  
301 infection<sup>14,34</sup>. Extensive efforts are therefore now invested into establishing the levels  
302 at which vaccine-generated antibodies protect against infection, aiming to facilitate  
303 rapid licensure of new vaccine platforms, support recommendations for vaccine

304 boosters and inform public health decisions. One such effort recently presented an  
305 80% vaccine efficacy against symptomatic SARS-COV-2 infection at 264 BAU/ml,  
306 declining to 60% vaccine efficacy at 54 BAU/ml<sup>35</sup>. These estimates were derived  
307 from a cohort vaccinated with the ChAdOx1 nCoV-19 vaccine, but similar levels are  
308 shown for mRNA vaccines<sup>36</sup>. Although these correlates require validation in further  
309 cohorts, our findings show that antibody titres have declined below these thresholds  
310 in a portion of study participants within 3-7 months from the second vaccine dose.  
311 Importantly, the estimations were derived in eras with a dominance of the Alpha  
312 variant, and the estimated titres may provide lower efficacy against infection with the  
313 current globally spreading Delta variant<sup>37-39</sup>, which seems to have a higher  
314 transmissibility<sup>40,41</sup>.

315  
316 Optimal dose interval has been proposed to convey better vaccine efficacy via  
317 improved memory formation<sup>17</sup>. A longer interval may indeed generate an improved  
318 memory formation, albeit at the price of a suboptimal protection during the longer  
319 interval between first and second dose in SARS-CoV-2 naïve populations. Although  
320 no significant differences in binding antibody titres, a slight elevation in pseudo-  
321 neutralization titres were found between the 3-4 week and 6-8 week dose interval in  
322 SARS-CoV-2 naïve participants, could indicate improved memory formation in the  
323 latter<sup>42</sup>. Continued studies are needed to address potential differences in longevity of  
324 the immunological memory induced by different prime boost intervals and  
325 combinations of various vaccine platforms, as well as the optimal timing of additional  
326 vaccine doses.

327  
328 This study is limited by the observational and single-centre nature. The study cohort  
329 moreover comprised HCW, and a majority of women of general working age.  
330 Antibody trajectories may differ in older populations, and in settings without repeated  
331 viral encounters with potential boosting of the immune memory.

332  
333 In summary, our findings of a considerable antibody decline over 3-7 months,  
334 paralleled with reports of waning vaccine effectiveness within the same time frame,  
335 supports the administration of a third vaccine dose, particularly in individuals with risk  
336 factors for severe COVID-19. However, the striking and sustained increased titres  
337 and neutralizing breadth of antibodies in previously SARS-CoV-2 infected vaccinees

338 as compared to SARS-CoV-2 naive vaccinees highlights the strong impact of  
339 infection prior to vaccination. These findings suggest that prior infection should be  
340 taken into consideration when planning booster doses and design of current and  
341 future SARS-CoV-2 vaccine programs.

342

343

#### 344 **Declaration of Interests**

345 SoH has participated on AstraZeneca COVID-19 SCG Virtual Advisory Board.

346 Otherwise, the authors declare no competing interests.

347

#### 348 **Acknowledgements**

349 This work was funded by Jonas & Christina af Jochnick foundation; Lundblad family  
350 foundation; Region Stockholm; Knut and Alice Wallenberg foundation; Science for  
351 Life Laboratory (SciLifeLab); Erling-Persson family foundation; CIMED and the  
352 Swedish Research Council. The funders above had no role in the design and  
353 conduct of the study; collection, management, analysis, and interpretation of the  
354 data; preparation, review, or approval of the manuscript; and decision to submit the  
355 manuscript for publication.

356

#### 357 **Data sharing**

358 The anonymized datasets generated during and/or analysed during the current study  
359 are available from the corresponding author on reasonable request.

360

361

#### 362 **References**

- 363 1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA  
364 Covid-19 Vaccine. *New England Journal of Medicine* 2020;383:2603-15.
- 365 2. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1  
366 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised  
367 controlled trials in Brazil, South Africa, and the UK. *Lancet* 2021;397:99-111.
- 368 3. Thomas SJ, Moreira ED, Jr., Kitchin N, et al. Safety and Efficacy of the BNT162b2  
369 mRNA Covid-19 Vaccine through 6 Months. *N Engl J Med* 2021.
- 370 4. Goldberg Y, Mandel M, Bar-On YM, et al. Waning immunity of the BNT162b2  
371 vaccine: A nationwide study from Israel. *medRxiv* 2021:2021.08.24.21262423.

- 372 5. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 Vaccine Booster  
373 against Covid-19 in Israel. *N Engl J Med* 2021;385:1393-400.
- 374 6. Pouwels KB, Pritchard E, Matthews PC, et al. Impact of Delta on viral burden and  
375 vaccine effectiveness against new SARS-CoV-2 infections in the UK. *medRxiv*  
376 2021:2021.08.18.21262237.
- 377 7. Shrotri M, Navaratnam AMD, Nguyen V, et al. Spike-antibody waning after second  
378 dose of BNT162b2 or ChAdOx1. *Lancet* 2021;398:385-7.
- 379 8. Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-  
380 19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective  
381 cohort study. *The Lancet*.
- 382 9. Goel RR, Apostolidis SA, Painter MM, et al. Distinct antibody and memory B cell  
383 responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. *Sci*  
384 *Immunol* 2021;6.
- 385 10. Mazzoni A, Di Lauria N, Maggi L, et al. First-dose mRNA vaccination is sufficient to  
386 reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from  
387 COVID-19. *J Clin Invest* 2021;131.
- 388 11. Painter MM, Mathew D, Goel RR, et al. Rapid induction of antigen-specific CD4(+)  
389 T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA  
390 vaccination. *Immunity* 2021;54:2133-42.e3.
- 391 12. Oberhardt V, Luxenburger H, Kemming J, et al. Rapid and stable mobilization of  
392 CD8(+) T cells by SARS-CoV-2 mRNA vaccine. *Nature* 2021;597:268-73.
- 393 13. Havervall S, Ng H, Falk AJ, et al. Robust humoral and cellular immune responses and  
394 low risk for reinfection at least eight months following asymptomatic to mild COVID-19. *J*  
395 *Intern Med* 2021.
- 396 14. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly  
397 predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med*  
398 2021;27:1205-11.
- 399 15. Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 Breakthrough Infections in  
400 Vaccinated Health Care Workers. *N Engl J Med* 2021.
- 401 16. Kristiansen PA, Page M, Bernasconi V, et al. WHO International Standard for anti-  
402 SARS-CoV-2 immunoglobulin. *Lancet (London, England)* 2021;397:1347-8.
- 403 17. Sallusto F, Lanzavecchia A, Araki K, Ahmed R. From vaccines to memory and back.  
404 *Immunity* 2010;33:451-63.

- 405 18. Cho A, Muecksch F, Schaefer-Babajew D, et al. Anti-SARS-CoV-2 receptor binding  
406 domain antibody evolution after mRNA vaccination. *Nature* 2021.
- 407 19. Krammer F, Srivastava K, Alshammary H, et al. Antibody Responses in Seropositive  
408 Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. *N Engl J Med* 2021;384:1372-  
409 4.
- 410 20. Stamatatos L, Czartoski J, Wan YH, et al. mRNA vaccination boosts cross-variant  
411 neutralizing antibodies elicited by SARS-CoV-2 infection. *Science* 2021.
- 412 21. Wang Z, Schmidt F, Weisblum Y, et al. mRNA vaccine-elicited antibodies to SARS-  
413 CoV-2 and circulating variants. *Nature* 2021;592:616-22.
- 414 22. Lucas C, Vogels CBF, Yildirim I, et al. Impact of circulating SARS-CoV-2 variants  
415 on mRNA vaccine-induced immunity. *Nature* 2021.
- 416 23. Ebinger JE, Fert-Bober J, Printsev I, et al. Antibody responses to the BNT162b2  
417 mRNA vaccine in individuals previously infected with SARS-CoV-2. *Nat Med* 2021;27:981-  
418 4.
- 419 24. Havervall S, Marking U, Greilert-Norin N, et al. Antibody responses after a single  
420 dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-  
421 CoV-2. *EBioMedicine* 2021;70:103523.
- 422 25. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S.  
423 Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. *New England Journal*  
424 *of Medicine* 2021;384:2092-101.
- 425 26. Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 Vaccination in a Large  
426 Health Care Organization. *New England Journal of Medicine* 2021.
- 427 27. Rudberg AS, Havervall S, Manberg A, et al. SARS-CoV-2 exposure, symptoms and  
428 seroprevalence in healthcare workers in Sweden. *Nat Commun* 2020;11:5064.
- 429 28. Havervall S, Rosell A, Phillipson M, et al. Symptoms and Functional Impairment  
430 Assessed 8 Months After Mild COVID-19 Among Health Care Workers. *JAMA* 2021.
- 431 29. Hober S, Hellström C, Olofsson J, et al. Systematic evaluation of SARS-CoV-2  
432 antigens enables a highly specific and sensitive multiplex serological COVID-19 assay. *Clin*  
433 *Transl Immunology* 2021;10:e1312.
- 434 30. Varnaite R, Garcia M, Glans H, et al. Expansion of SARS-CoV-2-Specific Antibody-  
435 Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19  
436 Patients. *J Immunol* 2020;205:2437-46.
- 437 31. Parry H, Bruton R, Stephens C, et al. Extended interval BNT162b2 vaccination  
438 enhances peak antibody generation in older people. *medRxiv* 2021:2021.05.15.21257017.

- 439 32. Patel MM, Thornburg NJ, Stubblefield WB, et al. Change in Antibodies to SARS-  
440 CoV-2 Over 60 Days Among Health Care Personnel in Nashville, Tennessee. *JAMA* 2020.
- 441 33. Plotkin SA. Correlates of protection induced by vaccination. *Clinical and vaccine*  
442 *immunology : CVI* 2010;17:1055-65.
- 443 34. Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a  
444 protective correlate for COVID-19 vaccines. *Vaccine* 2021;39:4423-8.
- 445 35. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and  
446 asymptomatic SARS-CoV-2 infection. *Nature medicine* 2021.
- 447 36. Gilbert PB, Montefiori DC, McDermott A, et al. Immune Correlates Analysis of the  
448 mRNA-1273 COVID-19 Vaccine Efficacy Trial. *medRxiv* 2021:2021.08.09.21261290.
- 449 37. Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in  
450 Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *Lancet*  
451 2021;397:2461-2.
- 452 38. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines  
453 against the B.1.617.2 (Delta) Variant. *New England Journal of Medicine* 2021.
- 454 39. Wall EC, Wu M, Harvey R, et al. Neutralising antibody activity against SARS-CoV-2  
455 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. *Lancet* 2021;397:2331-3.
- 456 40. Ong SWX, Chiew CJ, Ang LW, et al. Clinical and virological features of SARS-CoV-  
457 2 variants of concern: a retrospective cohort study comparing B.1.1.7 (Alpha), B.1.315 (Beta),  
458 and B.1.617.2 (Delta). *Clin Infect Dis* 2021.
- 459 41. Teyssou E, Delagrèverie H, Visseaux B, et al. The Delta SARS-CoV-2 variant has a  
460 higher viral load than the Beta and the historical variants in nasopharyngeal samples from  
461 newly diagnosed COVID-19 patients. *J Infect* 2021;83:e1-e3.
- 462 42. Pettini E, Pastore G, Fiorino F, Medagliani D, Ciabattini A. Short or Long Interval  
463 between Priming and Boosting: Does It Impact on the Vaccine Immunogenicity? *Vaccines*  
464 2021;9:289.
- 465  
466  
467  
468  
469  
470  
471  
472

473 **Tables**

474

	SARS-CoV-2 naïve			SARS-CoV-2 recovered		
	N	Age (IQR)	Female (%)	N	Age (IQR)	Female (%)
<b>BNT162b2 (3-4 weeks d.i.)</b>						
<b>Total</b>	<b>262</b>			<b>75</b>		
6 weeks p.v. (5-8)	<b>69</b>	50 (40-56)	84	<b>27</b>	50 (41-55)	81
12 weeks p.v. (11-14)	<b>175</b>	51 (40-57)	90	<b>52</b>	48 (39-56)	81
29 weeks p.v. (27-30)	<b>246</b>	50 (40-57)	87	<b>68</b>	49 (39-57)	82
<b>BNT162b2 (6-8 weeks d.i.)</b>						
<b>Total</b>	<b>36</b>			<b>36</b>		
12 weeks p.v. (11-14)	<b>36</b>	61 (54-62)	92	<b>36</b>	54 (40-60)	86
<b>ChAdOx1 nCoV-19 (10-12 weeks d.i.)</b>						
<b>Total</b>	<b>61</b>			<b>47</b>		
3 weeks p.v. (2-3)	<b>48</b>	52 (42-57)	90	<b>35</b>	52 (44-58)	86
14 weeks p.v. (13-15)	<b>56</b>	51 (38-56)	89	<b>44</b>	52 (44-57)	86

**Table 1. Demographics of study participants.** Age is presented as median with IQR; inter-quartile range. Weeks post second vaccine dose refers to point in time where sampling occurred and are presented as median together with the range. d.i.; dose interval, p.v.; post second vaccine dose.

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

	SARS-CoV-2 naïve		SARS-CoV-2 recovered	
	GMTs	95% CI	GMTs	95% CI
<b>SARS-CoV-2 wild type IgG (BAU/ml)</b>				
BNT162b2 (3-4 weeks d.i.)				
6 weeks p.v. (5-8)	981	(853-1128)	1875	(1222-2878)
12 weeks p.v. (11-14)	470	(430-513)	1278	(911-1793)
29 weeks p.v. (27-30)	148	(135-162)	524	(396-694)
BNT162b2 (6-8 weeks d.i.)				
12 weeks p.v. (11-14)	535	(414-692)	1345	(1043-1735)
ChAdOx1 nCoV-19 (10-12 weeks d.i.)				
3 weeks p.v. (2-3)	195	(137-275)	1350	(954-1910)
14 weeks p.v. (13-15)	105	(86-129)	591	(438-798)
<b>Pseudo-neutralizing Ab (wild type variant) (AU/ml)</b>				
BNT162b2 (3-4 weeks d.i.)				
6 weeks p.v. (5-8)	15.5	(13.5-17.7)	62.2	(33.0-117.2)
12 weeks p.v. (11-14)	8.5	(7.6-9.5)	27.2	(18.2-40.8)
29 weeks p.v. (27-30)	4.7	(4.5-5.0)	12.1	(9.7-15.2)
BNT162b2 (6-8 weeks d.i.)				
12 weeks p.v. (11-14)	10.9	(8.6-13.8)	30.2	(20.7-44.0)
ChAdOx1 nCoV-19 (10-12 weeks d.i.)				
3 weeks p.v. (2-3)	5.7	(5.1-6.3)	16.7	(11.9-23.4)
14 weeks p.v. (13-15)	4.0	(3.6-4.5)	12.7	(9.5-16.9)
<b>Pseudo-neutralizing Ab (Delta variant) (AU/ml)</b>				
BNT162b2 (3-4 weeks d.i.)				
6 weeks p.v. (5-8)	21.9	(18.1-26.5)	62.6	(30.8-127.0)
12 weeks p.v. (11-14)	8.4	(7.1-9.9)	30.1	(20.4-44.5)
29 weeks p.v. (27-30)	4.8	(4.0-5.7)	17.5	(13.7-22.2)
BNT162b2 (6-8 weeks d.i.)				
12 weeks p.v. (11-14)	14.6	(11.5-18.5)	40.1	(29.2-55.2)
ChAdOx1 nCoV-19 (10-12 weeks d.i.)				
3 weeks p.v. (2-3)	8.0	(7.1-9.0)	24.2	(18.4-31.7)
14 weeks p.v. (13-15)	2.7	(1.6-4.3)	16.1	(10.9-23.6)


**Table 2. Geometric mean titers (GMTs) of SARS-CoV-2 wild type spike IgG and pseudo-neutralizing antibodies in the different study groups.** Weeks post second vaccine dose refers to point in time where sampling occurred and are presented as median together with the range. CI; confidence interval, Ab; antibodies, d.i.; dose interval, p.v.; post second vaccine dose, AU; arbitrary unit, BAU; binding antibody unit.

490

491

492

493 **Figures**



494

495

496 **Figure 1. Timeline for vaccination and sample collection.** The cohort is divided  
497 into participants receiving BNT162b2 with a 3-4 week and a 6–8 week dose interval  
498 and ChAdOx1 nCoV-19 with a 10-12 week dose interval. Blue characters represent  
499 vaccinees that received BNT162b2 and yellow characters represent vaccinees that  
500 received ChAdOx1 nCoV-19. Light colored characters represent SARS-CoV-2 naïve  
501 and dark colored characters represent participants with SARS-CoV-2 infection prior  
502 vaccination. Test tubes represent time for blood sampling and syringes represent  
503 time for vaccination. w; weeks. d.i.; dose interval.

504

505

506

507

508

509

510

511


512

513

514

515


516



517

518 **Figure 2. Binding and pseudo-neutralizing antibody titers over time following**  
519 **BNT162b2 and ChAdOx1 nCoV-19 vaccination with and without prior SARS-**  
520 **CoV-2 infection. A) Binding antibody titers against SARS-CoV-2 wild type over 7**  
521 **months following the second BNT162b2 dose and 3 months following the second**  
522 **ChAdOx1 nCoV-19 dose in SARS-CoV-2 recovered and naïve vaccinees, B)**  
523 **pseudo-neutralizing antibodies against the wild type over 7 months following the**  
524 **second BNT162b2 dose and 3 months following the second ChAdOx1 nCoV-19 dose**  
525 **in SARS-CoV-2 recovered and naïve vaccinees, and C) pseudo-neutralizing**

526 antibodies against the Delta variant type over 7 months following the second  
527 BNT162b2 dose and 3 months following the second ChAdOx1 nCoV-19 dose in  
528 SARS-CoV-2 recovered and naïve vaccinees. Dots and crosses represent geometric  
529 mean titers and bars represent 95 % CI. Solid lines represent SARS-CoV-2  
530 recovered vaccinees and dotted lines represent SARS-CoV-2 naïve vaccinees. WT;  
531 wild type, BAU; binding antibody units, AU; arbitrary units.  
532



533

534 **Figure 3. Neutralizing capacity over time.** Neutralizing capacity A) 3 months and  
535 B) 7 months post BNT162b2 vaccination and C) 3 months post ChAdOx1 nCoV-19  
536 vaccination against ten SARS-CoV-2 variants including the wild type (WT), B.1.1.7  
537 (Alpha), B.1.351 (Beta), B.1.526.1 (New York), B.1.617 (India), B.1.617.1 (Kappa),

538 B.1.617.2 (Delta), B.1.617.3 (India), P.1 (Gamma), and P.2 (Zeta) variants. Dots  
539 represent geometric mean titers and bars represent 95 % CI. Dark colored dots  
540 represent SARS-CoV-2 recovered vaccinees and light colored dots represent SARS-  
541 CoV-2 naïve vaccinees.